Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review.
Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A. Vegivinti CTR, et al. Among authors: ramachandra n. Exp Hematol Oncol. 2023 Jul 8;12(1):60. doi: 10.1186/s40164-023-00422-1. Exp Hematol Oncol. 2023. PMID: 37422676 Free PMC article. Review.
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A. Schinke C, et al. Among authors: ramachandra n. Blood. 2015 May 14;125(20):3144-52. doi: 10.1182/blood-2015-01-621631. Epub 2015 Mar 25. Blood. 2015. PMID: 25810490 Free PMC article.
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A. Bachegowda L, et al. Among authors: ramachandra n. Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10. Cancer Res. 2016. PMID: 27287719 Free PMC article.
STAT3 inhibition as a therapeutic strategy for leukemia.
Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A. Kanna R, et al. Among authors: ramachandra n. Leuk Lymphoma. 2018 Sep;59(9):2068-2074. doi: 10.1080/10428194.2017.1397668. Epub 2017 Nov 22. Leuk Lymphoma. 2018. PMID: 29164994 Review.
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A. Shastri A, et al. Among authors: ramachandra n. J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30252677 Free PMC article.
The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation.
Adrianzen-Herrera D, Choudhary G, Gordon-Mitchell S, Ramachandra N, Bhagat T, Zhang H, Aluri S, Shastri A, Steidl U, Will B, Yang WL, Mahler M, Eichenbaum G, Guha C, Verma A. Adrianzen-Herrera D, et al. Among authors: ramachandra n. Leuk Lymphoma. 2020 Oct;61(10):2453-2465. doi: 10.1080/10428194.2020.1775213. Epub 2020 Jun 24. Leuk Lymphoma. 2020. PMID: 32578476
ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, Zhang J, Dolatshad H, Tittrea V, Tatwavedi D, Singh S, Lee J, Sun T, Steidl U, Shastri A, Inoue D, Abdel-Wahab O, Pellagatti A, Gavathiotis E, Boultwood J, Verma A. Rahmani NE, et al. Among authors: ramachandra n. Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0. Blood Cancer J. 2021. PMID: 34548471 Free PMC article.
Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer.
Aggarwal RK, Luchtel RA, Machha V, Tischer A, Zou Y, Pradhan K, Ashai N, Ramachandra N, Albanese JM, Yang JI, Wang X, Aluri S, Gordon S, Aboumohamed A, Gartrell BA, Hafizi S, Pullman J, Shenoy N. Aggarwal RK, et al. Among authors: ramachandra n. Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):e2106947118. doi: 10.1073/pnas.2106947118. Proc Natl Acad Sci U S A. 2021. PMID: 34551979 Free PMC article.
111 results